These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31584494)

  • 1. Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.
    Liu C; Liu T; Zhang J; Baum RP; Yang Z
    Clin Nucl Med; 2019 Nov; 44(11):876-878. PubMed ID: 31584494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
    Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
    Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
    Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
    Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
    Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
    Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
    Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined
    Adnan A; Basu S
    J Nucl Med Technol; 2020 Sep; 48(3):292-294. PubMed ID: 32358042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA: A Chance for 177Lu-DOTATATE Therapy?
    Nesari Javan F; Aryana K; Askari E
    Clin Nucl Med; 2021 Sep; 46(9):e480-e482. PubMed ID: 34028407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
    Assadi M; Pirayesh E; Rekabpour SJ; Zohrabi F; Jafari E; Nabipour I; Esmaili A; Amini A; Ahmadzadehfar H
    Clin Nucl Med; 2019 Dec; 44(12):978-980. PubMed ID: 31689280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
    Wei X; Schlenkhoff C; Schwarz B; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2017 Sep; 42(9):704-706. PubMed ID: 28719450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with
    Adnan A; Basu S
    J Nucl Med Technol; 2020 Mar; 48(1):36-39. PubMed ID: 31401619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 177 Lu-DOTATATE Therapy in a Case of Castrate-Resistant Prostate Cancer With Neuroendocrine Differentiation.
    Shu Q; Li X; Chen X; Chen Y; Cai L
    Clin Nucl Med; 2023 Aug; 48(8):e371-e373. PubMed ID: 37276491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation exposure after
    Mair C; Warwitz B; Fink K; Scarpa L; Nilica B; Maffey-Steffan J; Buxbaum S; Virgolini IJ
    Ann Nucl Med; 2018 Aug; 32(7):499-502. PubMed ID: 29797003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.